Nightstar Therapeutics (NASDAQ:NITE)‘s stock had its “outperform” rating restated by equities researchers at Wedbush in a report released on Thursday. They currently have a $31.00 price objective on the stock. Wedbush’s target price points to a potential upside of 164.96% from the company’s current price. Wedbush also issued estimates for Nightstar Therapeutics’ FY2022 earnings at $0.83 EPS.
A number of other analysts have also recently commented on the stock. Mizuho reissued a “buy” rating and set a $20.00 target price on shares of Nightstar Therapeutics in a research note on Thursday. Chardan Capital assumed coverage on shares of Nightstar Therapeutics in a research note on Wednesday, January 3rd. They set a “buy” rating and a $40.00 target price for the company. Six investment analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and a consensus price target of $28.50.
NITE stock opened at $11.70 on Thursday. The stock has a market cap of $346.47 and a PE ratio of -7.18. Nightstar Therapeutics has a 52 week low of $10.01 and a 52 week high of $24.93.
A number of hedge funds and other institutional investors have recently made changes to their positions in NITE. Ameriprise Financial Inc. purchased a new stake in Nightstar Therapeutics during the 3rd quarter valued at about $5,761,000. Essex Investment Management Co. LLC purchased a new stake in Nightstar Therapeutics during the 4th quarter valued at about $1,771,000. Alyeska Investment Group L.P. purchased a new stake in Nightstar Therapeutics during the 3rd quarter valued at about $1,920,000. Nationwide Fund Advisors purchased a new stake in Nightstar Therapeutics during the 3rd quarter valued at about $1,196,000. Finally, Citadel Advisors LLC purchased a new stake in Nightstar Therapeutics during the 3rd quarter valued at about $240,000. 29.06% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “Nightstar Therapeutics (NITE) Rating Reiterated by Wedbush” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/04/07/nightstar-therapeutics-nite-rating-reiterated-by-wedbush-2.html.
Nightstar Therapeutics Company Profile
Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate includes NSR-REP1, a candidate that has completed Phase 1/2 clinical trial for the treatment of patients with choroideremia.
Receive News & Ratings for Nightstar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.